Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
J Pediatr Gastroenterol Nutr ; 59(3): 334-9, 2014 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-24854897

RESUMO

OBJECTIVES: The aim of the present study was to assess the prevalence and patterns of complementary and alternative medicine (CAM) use among pediatric patients with gastrointestinal (GI) disorders at academic clinics in Canada. METHODS: The survey was carried out at 2 hospital-based gastroenterology clinics: the Stollery Children's Hospital in Edmonton and the Children's Hospital of Eastern Ontario (CHEO) in Ottawa. RESULTS: CAM use at the Stollery was 83% compared with 36% at CHEO (P < 0.001). The most common reason for not using CAM was lack of knowledge about it. Most respondents felt comfortable discussing CAM in their clinic and wanted more information on CAM. The most common CAM products being taken were multivitamins (91%), calcium (35%), vitamin C (32%), probiotics (14%), and fish oil/omega-3 fatty acids (13%). The most common CAM practices being used were massage (43%), chiropractic (27%), faith healing (25%), and relaxation (18%). Most respondents believed that CAM was helpful, and most of the 23 reported adverse effects were minor. Seven were reported as moderate, and 3 were reported as severe. Many (42%) patients used CAM at the same time as prescription medicines, and of these patients, concurrent use was discussed with their physician (76%) or pharmacist (52%). CONCLUSIONS: CAM use is high among pediatric patients with GI disorders and is much greater among those in Edmonton than in Ottawa. Most respondents reported their CAM use as helpful, with little or no associated harm. Many patients fail to disclose their concurrent use of CAM and conventional medicines to their doctors, increasing the likelihood of interactions.


Assuntos
Terapias Complementares/estatística & dados numéricos , Doenças do Sistema Digestório/terapia , Conhecimentos, Atitudes e Prática em Saúde , Centros Médicos Acadêmicos , Adolescente , Adulto , Alberta , Cuidadores/estatística & dados numéricos , Criança , Pré-Escolar , Terapias Complementares/efeitos adversos , Suplementos Nutricionais/estatística & dados numéricos , Cura pela Fé/estatística & dados numéricos , Feminino , Humanos , Masculino , Manipulação Quiroprática/estatística & dados numéricos , Massagem/estatística & dados numéricos , Pessoa de Meia-Idade , Ontário , Ambulatório Hospitalar , Relações Médico-Paciente , Probióticos/uso terapêutico , Terapia de Relaxamento/estatística & dados numéricos
2.
Biochem Biophys Res Commun ; 436(1): 79-84, 2013 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-23707942

RESUMO

The underlying mechanisms of microRNA deregulation in cancer cells include epigenetic modifications, which play a crucial role in carcinogenesis. We demonstrate that numerous microRNAs are induced in renal cell carcinoma cell lines after treatment with inhibitors of the DNA-methyltransferase (5-aza-2'-deoxycytidine) and the histone-deacetylase (suberoylanilide hydroxamic acid). We provide evidence that enrichment of H3 and H3K18 acetylation at the miR-9 promoter is causative for re-expression, while DNA hypermethylation remains unchanged. Our experiments show that the treatment with the epigenetic drugs causes re-expression of silenced microRNAs with putative tumor suppressive function in ccRCC cell lines.


Assuntos
Carcinoma de Células Renais/metabolismo , Epigênese Genética , Neoplasias Renais/metabolismo , MicroRNAs/metabolismo , Azacitidina/análogos & derivados , Azacitidina/farmacologia , Carcinoma de Células Renais/genética , Linhagem Celular Tumoral , Proliferação de Células , Sobrevivência Celular , Metilação de DNA , Metilases de Modificação do DNA/metabolismo , Decitabina , Regulação Neoplásica da Expressão Gênica , Inativação Gênica , Histona Desacetilases/metabolismo , Histonas/metabolismo , Humanos , Ácidos Hidroxâmicos/farmacologia , Neoplasias Renais/genética , Regiões Promotoras Genéticas , RNA/metabolismo , Vorinostat
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA